More specifically, IFN-γ and IL-2 intracellular levels were assessed upon BTLA activation or blockade in PBMCs from 8 patients with CLL (Fig. 3A and Supplementary Figure S1). The gene discussed is IL2; the disease is B-cell chronic lymphocytic leukemia.